Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture of ORENCIA
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. FDA has approved the company’s biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA® (abatacept).
The Devens facility, a state-of-the-art bulk biologics manufacturing facility, employs roughly 300 scientists, engineers, bioprocess operators, quality specialists and other skilled workers.
The Devens facility, a state-of-the-art bulk biologics manufacturing facility, employs roughly 300 scientists, engineers, bioprocess operators, quality specialists and other skilled workers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
- Lazard Global Total Return fund declares $0.1534 monthly distribution
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
